에 대한 최신 뉴스 Absci (NASDAQ:ABSI) 주식

Absci

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Equities

News

Markets

ETFs

$BTC

ABSI

ARKW

COIN

ROKU

TDOC

VERV

월요일에는 캐시 우드가 주도하는 아크 인베스트(Ark Invest)가 몇 가지 중요한 거래를 했으며, 그 가운데 코인베이스 글로벌(NASDAQ:COIN)의 거래가 주목을 받았다. 이는 특히 암호화폐의 경우 격동적인 시장 시나리오 속에서 발생했다.
코인 거래

아크 인베스트는 비트코인이 $62,000 아래로 하락하면서 코인베이스 주식을 매도

ARKF

ARKG

ARKK

ARKX

HOOD

MRNA

PLTR

수요일에 영향력 있는 투자자인 캐시 우드가 이끌고 있는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:HOOD), 모더나(NASDAQ:MRNA), 팔란티어 테크놀로지스(NYSE:PLT

아크 인베스트: 비트코인 하락에 로빈후드 매도, 모더나 매도, 팔란티어와 AMD 주식 매수

Absci Corp

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) .

Guidance

GPOR

Gulfport Energy Full Year 2024: Drilling and completion capex guidance cut to $325M-$335M.

Loop Capital analyst Garik Shmois maintains Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with a Buy and lowers the price target from $105 to $100.

Price Target

Analyst Ratings

Loop Capital Maintains Buy on Knife River Holding, Lowers Price Target to $100

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $330 to $280.

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $280

It's Election day! Voters are visiting polling locations and social media mavens are sharing opinions and local reports in megathreads, polls and comments on Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Here are some notable threads to follow for election <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">coverage on Reddit.&nbsp;</a>
Polls Open: Subreddit r/politics has over 8.5 million subscribers and features a <a href="https://www.reddit.com/r/politics/comments/1gkefi6/rpolitics_2024_us_elections_live_thread_part_59/">live thread</a> with 59 parts titled, "2024 US Elections Live Thread, Part 59" which contains more than 3,200 comments, voter turnout reports from different locations and live commentary on election developments.&nbsp;
Subreddit r/moderatepolitics has 295,000 members and a <a href="https://www.reddit.com/r/moderatepolitics/">poll titled</a> "Who are you voting for in the 2024 US Presidential Election." At the time of publication, 2,100 Redditors selected Harris, 1,300 selected Trump, 301 selected Other and 842 responded with Not Voting.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41612293/reddit-stock-soars-after-strong-q3-results-q4-guidance-above-estimates-dauqs-grow-17-and-more">Reddit Stock Soars After Strong Q3 Results, Q4 Guidance Above Estimates: DAUq&#8217;s Grow 17% And More</a>
Reddit also features local subreddits like r/Pennsylvania, which has <a href="https://www.reddit.com/r/Pennsylvania/comments/1gjutyd/the_election_day_mega_thread/">a thread</a> titled, "The Election Day Mega Thread" where users can find coverage of the crucial swing state and voting guides and polling locations. The thread also provides local polling updates and news with first-hand accounts from voters across the state.&nbsp;
Where To Find Results: FiveThirtyEight, the data journalism outlet, will feature county-by-county data breakdowns as the polling results come in at its r/fivethirtyeight <a href="https://www.reddit.com/r/fivethirtyeight/">subreddit</a>. It also features discussions about polling accuracy and several live election megathreads.&nbsp;&nbsp;
The r/Journalism <a href="https://www.reddit.com/r/Journalism/">subreddit</a> will provide authoritative sources for results, including updates from the Associated Press and major networks, as well as discussions about result reporting methodology.&nbsp;
Reddit&#8217;s election coverage offers a blend of real-time updates and community engagement across various specialized subreddits, though most users recommend keeping multiple sources open for the most complete picture.&nbsp;
RDDT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Reddit shares ended Tuesday&#8217;s session 12.42% higher at $122.57.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">JPMorgan To Pay Investors $151 Million After SEC Flags &#8216;Various Law Violations&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

Politics

Tech

General

RDDT

Redditors Track Election Night: Must-Watch Threads For Trump Vs. Harris Showdown, Other Races

WIIM

WillScot Holdings shares are trading higher following a report suggesting activist investor TOMS has built a stake in the company and is pushing for a review.

JP Morgan analyst Kevin Yin upgrades Yum China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) from Neutral to Overweight and raises the price target from $35.5 to $60.

Upgrades

YUMC

JP Morgan Upgrades Yum China Holdings to Overweight, Raises Price Target to $60

With the first polling places about to close in what is <a href="https://www.benzinga.com/general/politics/24/11/41748843/trump-holds-edge-in-betting-markets-on-election-day-while-experts-call-tight-race-for-harris">expected to be a neck-and-neck election night</a>, reports from Georgia and Michigan say those two swing states are seeing record-high turnout.
What Happened: Turnout in Philadelphia is also reported to be extremely high, with Reuters reporting turnout as much as 50% higher in some precincts than in 2020. A big win in Philadelphia would go a long way toward delivering Pennsylvania &#8211; the largest and tightest swing state &#8211; to Kamala Harris.
At 4:39 p.m. EDT, Donald Trump wrote on Truth Social: &#8220;A lot of talk about massive CHEATING in Philadelphia. Law Enforcement coming!!!&#8221; 
A Philadelphia police spokesman <a href="https://fortune.com/2024/11/05/donald-trump-claims-cheating-police-philadelphia-pennsylvania/">told Fortune</a> they are &#8220;not aware of anything at this time.&#8221; 
Charlie Kirk of pro-Trump group Turning Point Action wrote earlier on X: &#8220;Turnout is mixed and not where we want it to be. We need more people to vote.&#8221;
Also Read: <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">2024 Election Stakes: Potential Sweeps, Split Outcomes In Congressional, Presidential Races</a>
Politico is <a href="https://www.politico.com/live-updates/2024/11/05/2024-elections-live-coverage-updates-analysis/turnout-high-in-georgia-00187458">reporting</a> that turnout in Georgia is on track to surpass 2020, and The Hill <a href="https://thehill.com/homenews/campaign/4973132-michigan-on-pace-to-break-voter-turnout-records-official-says/">says</a> that Michigan may break turnout records.
Why It Matters: High turnout in Philadelphia would be good news for Harris, but even a loss in Pennsylvania would not be fatal to Trump if he performs well in other swing states.
Georgia, Michigan and Pennsylvania were all key to Joe Biden&#8216;s victory in 2020.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">Trump Vs. Harris: 2024 Election Deadlocked, Final Emerson Poll Shows One Candidate With Small Edge Among Independents</a></li>
</ul>
Image: Shutterstock.

High Turnout Reported In Key States, Trump Baselessly Alleges 'Massive CHEATING' In Philadelphia

A new study <a href="https://tandfonline.com/doi/full/10.1080/21507740.2024.2303154">published</a> in AJOB Neuroscience reveals that most Americans are supportive of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost <a href="https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/">reported</a>, this approval, spanning across political lines, underscores public openness to the controlled use of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin for mental health treatment</a> and general well-being, despite remaining concerns for policy caution.
Psilocybin, a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule 1</a> drug in the U.S., has long been classified as having a high potential for abuse with no accepted medical use. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">recent clinical studies</a> suggest it may help alleviate symptoms of conditions such as treatment-resistant depression when administered under professional supervision. Unlike many medications, psilocybin is considered non-addictive, and studies have found it may also <a href="https://www.benzinga.com/markets/cannabis/24/09/41004196/psilocybin-found-to-be-as-effective-as-lexapro-in-treating-depression-researchers-say">enhance overall well-being</a> in healthy individuals.
This research aimed to explore public perceptions of psilocybin amid <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">recent legislative progress</a>, such as Oregon&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">allowing its therapeutic use</a>. Researchers surveyed 805 Americans, aged 18 to 92, providing background on psilocybin's effects, origin and legal status before asking about support for nationwide legalization.
<h3 class="wp-block-heading">Mental Health Treatment Vs. Well-Being Enhancement</h3>
Participants were presented with two scenarios involving supervised psilocybin use: one for mental health treatment and the other for personal well-being. A strong 89% of participants supported psilocybin use for mental health treatment, while 85% approved its use for well-being enhancement. Though medical use garnered slightly more support, both scenarios saw broad endorsement.
The results show bipartisan support for supervised psychedelic therapy, with younger and more liberal adults showing stronger approval. Older adults and conservatives were more cautious, while those valuing empathy and care were more supportive of psilocybin use in therapy
<h3 class="wp-block-heading">Navigating Caution Amid The Psychedelic Renaissance</h3>
The study also sheds light on the importance of tempering enthusiasm with scientific rigor. According to the researchers, the growing interest in psychedelics comes with the risk of overhyping benefits. Given the early stage of the field, both over- and understatements of trial results are not uncommon. As they noted, while psilocybin shows significant medical potential and a strong safety profile, current evidence doesn&#8217;t support rash conclusions beyond its use in the right context.
While the findings suggest broad public support for supervised psychedelic use, the study focused only on licensed environments, excluding unsupervised or recreational use. Future research could explore attitudes toward these higher-risk aspects.
<h3 class="wp-block-heading">Building Trust And Policy For The Future</h3>
The study authors stressed the need for trust-building and caution in shaping future policies. "If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust—then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being," they concluded.
With public support reaching bipartisan levels, the potential for psilocybin to become part of standard mental health care is closer to reality than ever, signaling a transformative shift in mental health treatment in the U.S.
Cover image made with AI

Cannabis

Psychedelics

Americans Favor Psilocybin For Mental Health Treatment, Study Finds

DA Davidson analyst Brian Holland maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $183 to $189.

FRPT

DA Davidson Maintains Buy on Freshpet, Raises Price Target to $189

Hut 8 Says Its Self-Mining Produced 100 BTC In October, Up From 85 BTC In September; Vega Site Buildout Advancing On Track For Q2 2025 Energization

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and lowers the price target from $94 to $90.

DA Davidson Maintains Neutral on Federal Signal, Lowers Price Target to $90

DA Davidson maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $55 to $48.

NSSC

DA Davidson Maintains Buy on NAPCO Security Techs, Lowers Price Target to $48

Emerson and its affiliates currently own 57.4% of the Company's outstanding common shares, based on their most recent Schedule 13D filing dated November 5, 2024.
The Board of Directors of AspenTech will follow an appropriate governance process and carefully review the proposal. No action is required by AspenTech shareholders at this time. &nbsp;

AZPN

Aspen Technology Confirms Receipt Of $240/Share Unsolicited Acquisition Proposal From Emerson; Asks Shareholders Not To Take Any Action Pending Review

DA Davidson analyst Brent Thielman maintains Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) with a Neutral and raises the price target from $41 to $47.

DA Davidson Maintains Neutral on Summit Materials, Raises Price Target to $47

PAAS

Pan American Silver Reaffirms Its 2024 Operating Outlook For Annual Production, Cash Costs And AISC, And Capital Expenditures

Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 3100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $716.10 million which beat the analyst consensus estimate of $699.01 million by 2.44 percent. This is a 16.19 percent increase over sales of $616.30 million the same period last year.

Earnings

Earnings Beats

Pan American Silver Q3 2024 Adj EPS $0.32 Beats $0.21 Estimate, Sales $716.10M Beat $699.01M Estimate

DA Davidson analyst Kevin Fitzsimmons maintains Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) with a Buy and lowers the price target from $41 to $38.

DA Davidson Maintains Buy on Origin Bancorp, Lowers Price Target to $38

DA Davidson analyst Gil Luria maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Neutral and raises the price target from $28 to $47.

DA Davidson Maintains Neutral on Palantir Technologies, Raises Price Target to $47

The 2024 U.S. presidential election between Vice President Kamala Harris and former President Donald Trump remains one of the closest in history, raising concerns over whether the U.S. Supreme Court may play a decisive role in <a href="https://www.benzinga.com/topic/2024-election">determining the outcome. </a>
As voters head to the polls, election-related legal battles already hint at the possibility of judicial involvement, The New York Times <a href="https://www.nytimes.com/2024/11/05/us/politics/election-supreme-court.html">reports</a>.
What Happened: Several election cases have reached the Supreme Court in recent weeks, including a decision to allow Virginia's removal of over 1,600 voters from its rolls and rulings affecting candidates and voters in battleground states. 
The court decided against removing Robert F. Kennedy Jr. from ballots in key states and authorized provisional ballots in Pennsylvania, after some mail-in ballots were deemed invalid. These cases showcase the judiciary's cautious approach to electoral involvement, although the court's conservative majority could still play a critical role if a close race sparks significant litigation, according to The New York Times.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41759661/us-election-jitters-meet-interest-rate-cut-assurance-why-feds-powell-may-offer-tr">US Election Jitters Meet Interest-Rate Cut Assurance: Why Fed&#8217;s Powell May Offer Traders A Safe Harbor This Week</a>
The Supreme Court's involvement would hinge on an exceptionally narrow vote margin in a critical state, experts say. Prof. Richard Pildes of New York University told The New York Times that a paper-thin margin in a state like Pennsylvania, with its 19 electoral votes, could increase the likelihood of a court ruling influencing the presidential outcome.
Still, experts are cautious, noting that the Supreme Court generally aims to avoid direct involvement in elections.
Beyond the presidential race, the stakes extend to congressional control. Democrats seek to retain the Senate and flip the House, while Republicans push for gains in both chambers. The outcomes in Senate races, including those in Montana and Ohio, could shift control, particularly if Democratic seats in battleground states like Michigan and <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">Pennsylvania face Republican challenges.</a> 
Why It Matters: A Supreme Court decision might not only impact the presidency but also influence control over Congress, setting a precedent for election litigation. In a scenario reminiscent of the Bush v. Gore case in 2000, if margins are close enough, legal challenges could escalate to the highest court. 
The potential for either party to control both chambers or split Congress suggests significant implications for the future of U.S. legislation and governance, The New York Times notes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41756372/robinhoods-election-contracts-hit-200-million-trades-on-election-day">Robinhood&#8217;s Election Contracts Hit 200 Million Trades On Election Day</a></li>
</ul>
This article was generated using artificial intelligence and was reviewed by Benzinga editors.
Photo: Shutterstock

Government

Legal

Supreme Court Could Step In If 2024 Election Remains Deadlocked

SMCI

Super Micro Computer CEO Says Don't Expect Negative Allocation From NVIDIA

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day. 

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

Absci started by Guggenheim at buy on pioneer status in AI drug design

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Absci: Embryonic Pipeline Looks Expensive Relative To Peers

20:15 EDT Cathie Wood's ARK Investment bought 447K shares of Absci (ABSI) today Published first on TheFly – the ultimate source for real-time, mark...

Cathie Wood's ARK Investment bought 447K shares of Absci today

20:13 EDT Cathie Wood's ARK Investment bought 401K shares of Absci (ABSI) today Published first on TheFly – the ultimate source for real-time, mark...

Cathie Wood's ARK Investment bought 401K shares of Absci today

ABCL

AZNCF

BSGM

EXAI

NVDA

RHHBF

RHHBY

RHHVF

RLAY

RXRX

SDGR

SNYNF

TEVA

TEVJF

Press Releases

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024

Health Care

Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

Absci to Participate in Upcoming Investor Conferences

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

TWST

Akebia Therapeutics

Altimmune

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Aura Biosciences

C4 Therapeutics

Emergent BioSolutions

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Foghorn Therapeutics

GRAIL

ITeos Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MeiraGTx Hldgs

Organogenesis Hldgs

Prime Medicine

Regenxbio

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Tevogen Bio Holdings

Valneva

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

Guggenheim

HC Wainwright & Co.

Keybanc

Morgan Stanley

Truist Securities

월요일에는 캐시 우드가 주도하는 아크 인베스트(Ark Invest)가 몇 가지 중요한 거래를 했으며, 그 가운데 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 거래가 주목을 받았다. 이는 특히 암호화폐의 경우 격동적인 시장 시나리오 속에서 발생했다.
코인 거래
이날 아크 인베스트의 가장 눈에 띄는 거래는 대표적인 암호화폐 거래소 플랫폼인 코인베이스와의 거래였다. 이번 거래는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ​​가격이 62,000달러 아래로 떨어지는 등 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39459091/coinbase-shares-tumble-with-bitcoin-whats-going-on-with-the-stock" target="_blank" rel="noopener" data-google-interstitial="false">암호화폐 시장이 상당한 변동성</a>을 겪고 있는 시기에 이루어졌다. 이러한 비트코인 ​​가격 하락은 코인베이스 주가에 직접적인 영향을 미쳤으며 월요일에도 하락세를 보였다.
코인베이스 주가는 월요일 정규 세션이 끝날 때 212.31달러를 기록했다. 이 회사는 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)를 통해 3,341개의 코인베이스 주식을 매도했다. 이 거래 금액은 709,327달러이다.
기타 중요한 거래:
<ul>
<li>텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG ETF에서 54,256주, ARKK ETF에서 61,606주를 매도했다.</li>
<li>앱사이이(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>): ARKG ETF를 통해 43,936주를 매수했다.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG ETF에서 10,570주, ARKK ETF에서 50,971주를 매도했다.</li>
<li>로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): ARKK ETF를 통해 32,989주를 매수했다.</li>
</ul>
다음 읽기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39448829/bitcoin-ethereum-dogecoin-fall-on-investor-worries-analyst-warns-of-king-cryptos-dip-below?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">투자자 우려로 비트코인, 이더리움, 도지코인 가격 하락</a>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에서 제공한 내용을 바탕으로 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 수정했습니다.

수요일에 영향력 있는 투자자인 캐시 우드가 이끌고 있는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) 및 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)와 관련한 주목할 만한 거래를 성사시켰다.
HOOD 거래
아크 인베스는 다수의 펀드들에서 로빈후드 마켓의 지분을 축소했다. ARK 금융기술 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 11만 3,329주를 팔았으며, ARK 혁신 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)는 44만 4,823주를 처분하고 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 3만 5,582주를 처분했습니다. 이 거래의 가치는 1,251만 달러에 해당한다.
이번 주, 로빈후드의 주가는 회사 이사회가 사업 및 현금 흐름의 지속적인 성장에 따라 주주들에게 가치를 돌려주는 것을 목표로 하는 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on" target="_blank" rel="noopener">자사주 매입 프로그램</a>을 승인한 후 급등했다. 경영진은 로빈후드의 주가 변동에 따라 속도를 조정하면서 2024년 3분기부터 2~3년에 걸쳐 자사주 매입을 완료할 계획이다.
수요일, 비트코인 (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)의 가격은 6만 7,000달러 선 주변을 맴돌았으며 이더리움의 가격은 3,800달러 밑으로 떨어져 최근 현물 ETF 흥분으로 인한 상승폭을 반납했다. 특히 로빈후드를 사용하면 대규모 소매 거래자 사용자 기반에서 암호화폐를 사고 팔 수 있다.
MRNA 거래
바이오테크 분야에서 아크 인베스트는 이틀 연속 모더나를 매각하면서, ARK 유전체 혁명 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)가 15,644주를 매도했고 주력 ARKK가 24,616주를 매도했다. 모더나의 종가 147.92달러를 고려하면 매각된 주식의 총 가치는 약 595만 달러이다. 이 결정은 모더나에 대한 노출을 줄이려는 <a href="https://www.benzinga.com/markets/equities/24/05/39053301/cathie-woods-ark-invest-scoops-up-shares-of-amd-and-palantir-dumps-moderna-stock-worth-4-4m" target="_blank" rel="noopener">아크의 최근 거래 패턴</a>과 일치한다.
PLTR 거래
이와 대조적으로 아크 인베스트는 파란티어 테크놀로지스 주식을 ARK 우주 탐사 &amp; 혁신 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)가 거의 532,000달러 상당의 25,403주를 인수함으로써 팔란티어에서의 입지를 강화했다. 팔란티어의 종가는 20.94달러였다. 이번 인수는 투자자들이 이 회사의 미래 성장 전망에 대해 추측함에 따라 팔란티어의 주가가 변동하는 가운데 이루어졌다.
AMD 거래
아크의 ARKW는 어드밴스드 마이크로 디바이시스(AMD)에서 약 161만 달러 상당의 9,725주를 매입하여 강세를 보였다. 이번 투자는 AMD와 <a href="https://www.benzinga.com/news/24/05/39060171/amd-expands-partnership-with-samsung-new-3nm-chips-to-boost-market-share" target="_blank" rel="noopener">삼성전자</a>의 파트너십 확대 소식이 나온 후 나온 것이다. 이 회사가 엔비디아 라이벌의 주식을 연속으로 구매한 것은 이번이 두 번째이다.
기타 중요한 거래: ARKG가 앱시 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) 37만 5,779주를 구매했다. ARKG는가든트 헬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) 3만 8,501주를 매수했다. ARKQ는 3D 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) 11만 6,232주에 대한 투자를 진행했다. ARKX는 텔레다인 테크놀러지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) 1,244주를 전략적으로 매수했다.
사진 제공: Ark Invest

Comments

Absci

뉴스

에 대한 최신 뉴스 Absci (NASDAQ:ABSI) 주식

화요일, 6월 25, 2024

목요일, 5월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌